698394-73-9

Usage

Uses

Used in Pharmaceutical Industry:
GSK-1605786 is used as a therapeutic agent for the treatment of autoimmune and inflammatory diseases, particularly for conditions involving the chemokine receptor CCR9. Its high selectivity and potency make it a promising candidate for targeted therapies.
Used in Cancer Research:
GSK-1605786 is used as a research tool for studying the role of CCR9 in cancer progression and metastasis. Its ability to inhibit CCL25-induced chemotaxis in various cell types, including human T cells and mouse and rat thymocytes, makes it valuable for investigating the mechanisms underlying CCR9-mediated cell migration and invasion in cancer.
Used in Drug Discovery:
GSK-1605786 serves as a lead compound for the development of novel CCR9 antagonists with improved pharmacological properties and therapeutic potential. Its allosteric binding mechanism and selectivity over other chemokine receptors provide a foundation for designing more effective and targeted drugs for various diseases.

Upstream product

• 15084-51-2 4-tert-butylbenzenesulfonyl chloride 
• 105192-42-5 (2-amino-5-chlorophenyl)(pyridin-4-yl)methanone 
• 65854-91-3 N-(4-chlorophenyl)-2,2-dimethylpropionamide 
• 55-22-1 pyridine-4-carboxylic acid 
• 52482-36-7 morpholin-4-yl(pyridin-4-yl)methanone 
• 106-47-8 4-chloro-aniline 
• 698394-72-8 4-tert-butyl-N-[4-chloro-2-(pyridine-4-carbonyl)-phenyl]-benzenesulfonamide 

Downstream Products

• 870556-03-9 4-chloro-2-(difluoro-pyridin-4-yl-methyl)-phenylamine 

Relevant academic research and scientific papers

Evaluation of tert-butyl isosteres: Case studies of physicochemical and pharmacokinetic properties, efficacies, and activities

The tert-butyl group is a common motif in medicinal chemistry. Its incorporation into bioactive compounds is often accompanied by unwanted property modulation, such as increased lipophilicity and decreased metabolic stability. Several alternative substituents are available for the drug discovery process. Herein, physicochemical data of two series of drug analogues of bosentan and vercirnon are documented as part of a comparative study of tert-butyl, pentafluorosulfanyl, trifluoromethyl, bicyclo[1.1.1]pentanyl, and cyclopropyl-trifluoromethyl substituents.

PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME

The present invention provides a prophylactic or therapeutic agent and a prophylactic or therapeutic method superior in the prophylaxis or treatment of Sjogren's syndrome. Provided are a prophylactic or therapeutic agent for Sjogren's syndrome, containing

A CRYSTALLINE FORM OF THE SODIUM SALT OF 4-TERT-BUTYL-N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENE SULFONAMIDE

A novel crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1- oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide and pharmaceutical compositions containing the same are disclosed. Processes for the preparation thereof and methods for use

ARYL SULFONAMIDES

The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.

ARYL SULFONAMIDES

Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.